Work

Abstract B247: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-b247

Authors: Jennifer J. Wheler, Anne M. Traynor, Howard H. Bailey, Steven Attia, Gerald S. Falchook, A. Douglas Laird, Linh Nguyen, Christian Scheffold, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Exelixis (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2064250326

Cites:

Cited by: 4

Related to: 10